As the U.S. Labor Market Slows...Investor Attention Shifts to 'Bio & Healthcare'

As the recent slowdown in the U.S. labor market has been confirmed, domestic investors' attention is shifting toward growth stocks expected to benefit from interest rate cuts, particularly 'bio & healthcare' new drug pipelines. On the 7th (local time), the U.S. Bureau of Labor Statistics under the Department of Labor announced that nonfarm payrolls in July decreased by 23,000 compared to the previous month. This is the exact opposite of the market expectation of an 83,000 increase. Additionally, the unemployment rate fell to 4.1% due to the impact of a decline in the labor force participation rate.

Against this macroeconomic backdrop, the biggest topic in the global pharmaceutical industry remains obesity and diabetes treatments. The transition of GLP-1 series treatments, previously centered on injectables, to oral formulations is rapidly progressing, and the development of 'oral insulin' that can be taken without injection is emerging as the next-generation axis of competition. In the domestic market, Samchundang Pharm is drawing attention as a company that aligns with these global trends.

From a Specialist in Ophthalmic Diseases to a Leading Player in New Drug Development

Samchundang Pharm, established in 1943, is a company that has grown by building a solid business foundation in the manufacturing of eye drops, including treatments for dry eye syndrome. According to Wikipedia, the company acquired Optus Pharmaceutical in 2013 and obtained EU GMP certification in 2015 and 2018, securing a bridgehead for overseas expansion.

However, the market's intense interest has recently focused beyond its existing ophthalmology business and toward its 'new drug pipeline.' In particular, the development pace of the oral insulin candidate 'SCD0503' is evaluated as a key variable that will determine the company's future value. According to a Newsis report, this substance is currently undergoing global Phase 1 clinical trials at the German clinical institution Profil, with dosing already completed for one-third of the total patients. The company aims to conclude Phase 1 clinical trials within the fourth quarter of this year.

However, it should be noted that this is merely a Phase 1 clinical trial, which is still an early stage. With subsequent procedures such as approval, additional clinical trials, and commercialization remaining, it is not possible to definitively determine actual revenue generation or commercialization timelines at this point.

Accelerating R&D Based on Stable Cash Flow

Samchundang Pharm's strategy can be summarized as a structure of reinvesting the stable cash flow generated from its existing ophthalmology business into the development of biosimilars and new pipelines. Thanks to this business structure, the company is evaluated among investors as one where both short-term earnings defense and long-term growth driven by new drug development can be expected simultaneously.

[※ This article is intended for informational purposes, and investment decisions and their associated responsibilities lie with the investor. As matters related to stocks and companies are highly volatile and fluid, please verify further through the latest disclosures and multiple sources before making investment decisions. This is an article partially assisted by AI.]